Sophiris Bio

About:

Sophiris Bio is a biopharmaceutical company that develops topsalysin for the treatment of urological diseases.

Top Investors: Warburg Pincus, Sofinnova Investments, Silicon Valley Bank, Aspire Capital Partners LLC

Description:

Sophiris Bio is a biotech company that develops a treatment for the symptoms of benign prostatic hyperplasia. Their product includes topsalysin for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia and for the treatment of low- to intermediate-risk prostate cancer.

Total Funding Amount:

$47.2M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

La Jolla, California, United States

Founded Date:

2002-01-01

Contact Email:

info(AT)sophirisbio.com

Founders:

Thomas Buckley

Number of Employees:

11-50

Last Funding Date:

2017-09-14

IPO Status:

Public

Industries: